Gilead Sciences Announces Acceptance of Viread Late Breaker Abstracts at Upcoming 14th International AIDS Conference

Forty-eight Week Data Evaluating Viread™ in Treatment-naïve Patients, Pharmacokinetic Data from Study of Viread and Didanosine to be Presented

Foster City, CA -- June 18, 2002

Gilead Sciences (Nasdaq: GILD) today announced the acceptance of two late breaker presentations at the 14th International AIDS Conference taking place in Barcelona, Spain, from July 7-12, 2002. The presentations include data from a 48-week analysis of the company's ongoing Phase III clinical trial (Study 903) of Viread™ (tenofovir disoproxil fumarate) and data from a pharmacokinetic study evaluating the effects of enteric-coated didanosine (Videx EC, ddI EC) and Viread when co-administered.

Clinical investigator Schlomo Staszewski, MD, University Hospital, J.W. Goethe-Universität, Frankfurt, Germany, will present 48-week safety and efficacy data from Study 903 of Viread (Abstract #LbOr17). This study was designed to compare the efficacy and safety of a treatment regimen of Viread, lamivudine (3TC) and efavirenz to a regimen of stavudine (d4T), lamivudine and efavirenz in 600 antiretroviral-naïve HIV patients. Study 903 will be presented on Friday, July 12 during the Late Breaker Session between 8:30 a.m. and 10:00 a.m. Preliminary results from this study were summarized in a press release issued on May 7, 2002. In addition, Andrew Cheng, MD, PhD, Gilead Sciences, will present data from Study 932, which evaluated the pharmacokinetic interactions of didanosine EC and Viread when co-administered in 28 individuals for a duration of 15 days. Study 932 (Abstract #LbPeB9026) will be presented as a poster on Thursday, July 11 from 12:00 p.m.- 2:00 p.m.

Viread will be the subject of an additional 12 posters or presentations during the International AIDS Conference. A schedule of presentations may be obtained from the International AIDS Conference Web site at www.AIDS2002.com. Late breaker abstracts will be made available to conference participants upon registration at the meeting and will be available from Gilead upon request.

About Gilead Sciences
Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes therapeutics to advance the care of patients suffering from life-threatening diseases worldwide. The company has five marketed products and focuses its research and clinical programs on anti-infectives, including antivirals, antifungals and antibacterials. Headquartered in Foster City, CA, Gilead has operations in the United States, Europe and Australia.

Return to Press Releases